Selective androgen receptor modulators (SARMs), such as enobosarm (GTx-024), increase lean mass and may improve function, but phase III results have been mixed and no agent has regulatory approval for sarcopenia [71]
The feeling of losing a big chunk of my days was never a positive one
Scott Butsch, who is director of obesity medicine at the Cleveland Clinic in Ohio, who was not involved in the research
Lilly has reported strong Phase 3 results, including 28.3% average weight loss over 80 weeks at the highest studied dose in one obesity trial, but the drug still requires regulatory review
It has several far-reaching consequences like increased incidence of heart diseases, diabetes, depression, reduced quality of life and even death
Should I stop semaglutide if a result is abnormal